Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Guardant Health (NASDAQ: GH) and increased the price target from $190 to $200. This adjustment reflects a positive outlook on the company's performance.